RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009.

“Modified sdRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC”

"We have continued to demonstrate our scientific and business leadership throughout 2009 and into 2010," said Noah D. Beerman, President and Chief Executive Officer of RXi. "We have advanced our therapeutic platform, strengthened our intellectual property position, published robust scientific findings in peer reviewed journals, presented broad-based applications of our proprietary compounds at leading RNAi conferences, and established research collaborations to further explore the use of our technology in additional therapeutic areas. Further, with our recent financing, we strengthened our balance sheet and are well positioned to execute on our 2010 goals, including selecting a product candidate to advance into development, refining the therapeutic focus for our rxRNA technology, and securing one or more corporate partnerships."

2009 and Other Recent Highlights

Corporate Highlights:

• Completed $16.2 million Public Offering. After deal-related expenses including placement agent fees and the repurchase of 675,000 shares of RXi stock from CytRx Corporation at a price of $5.70 per share, RXi received approximately $11.4 million in net proceeds from the offering that closed on March 26, 2010. Proceeds from the transaction will be used to meet working capital needs and for general corporate purposes.
• Appointed Noah D. Beerman as President and Chief Executive Officer. In November 2009, Noah D. Beerman joined RXi as its new President and Chief Executive Officer. Mr. Beerman also joined RXi's Board of Directors. Appointing a seasoned business leader was part of a planned succession in leadership with the goal of advancing RXi from a research-focused company to a company focused on product development and execution of therapeutic collaborations and partnerships. Mr. Beerman succeeded RXi's co-founder, Tod Woolf, Ph.D., who continues to serve as a member of RXi's Scientific Advisory Board.
• Completed $8.3 million Public Offering. After deal-related expenses including placement agent fees, RXi received approximately $7.8 million in net proceeds from the offering that closed on August 4, 2009. Proceeds from the transaction are being used to meet working capital needs and for general corporate purposes.
• Strengthened Intellectual Property Position. RXi filed multiple patent applications, acquired direct ownership of previously licensed RNAi delivery technology from Advirna LLC, and received notices of allowance on small interfering RNA sequence patents in-licensed from Thermo Fisher Scientific.
• Signed Multiple Research and Feasibility Agreements. In a concerted effort to accelerate the development of its proprietary rxRNA technology and other related technologies, RXi entered into research agreements with several undisclosed pharmaceutical and biotechnology companies.
• Appointed Two New Board Directors. As part of a continuing effort to add deep scientific and clinical development expertise to its Board of Directors, RXi added two new members to its Board during the first half of 2009, Richard Chin, M.D. and Rudolph Nisi, M.D. RXi's Board currently has 7 members.
• Expanded Management Team. In March 2009, Ramani Varanasi, MS, MBA joined the company as Vice President of Business Development. Ms. Varanasi has more than 15 years of experience in structuring, negotiating and executing strategic alliances, licenses and collaborations and in providing business development, management and strategic leadership in the pharmaceutical industry.
• Secured $25 Million Standby Equity Distribution Agreement. Under the terms of this agreement with Yorkville Advisors signed in January 2009, RXi has the option, at its sole discretion, to sell to Yorkville newly issued common shares, subject to certain conditions, in increments of up to $500,000 each over a two-year period for a total of up to $25 million in proceeds to RXi.
• Participated in Numerous Investor Events. Management participated in several investor focused conferences hosted by investment banks and other organizations. RXi also hosted an Analyst Day Event where senior management along with RXi co-founder and Nobel Laureate, Dr. Craig Mello, updated investors on RXi's corporate and scientific developments and 2009 goals.

Scientific Achievements:

• Publication of Data in Peer Reviewed Journals. An article entitled "Modified sdRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC" was published in the journal Nucleic Acids Research, January 2010. The data expands the understanding of how chemically modified RNAi duplexes interact with key proteins involved in the silencing pathway and that longer, modified duplexes can be highly potent target gene silencers. RXi also announced that new pre-clinical data on oral delivery of RNAi compounds was published by Michael Czech, Ph.D., co-founder of, and Scientific Advisor to, RXi Pharmaceuticals and Professor and Chair of Molecular Medicine and Professor of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School (UMMS) in the prestigious journal Nature Biotechnology. (Aouadi, et al, Nature, Vol. 458 (7242), pp. 1180-1184).
• Research Collaboration Focused on Ocular Disease. RXi initiated a research collaboration with Shalesh Kaushal, M.D., Ph.D., Chairman of the Department of Ophthalmology at The University of Massachusetts Medical School focused on the application of RXi's self-delivering RNAi (sd-rxRNA™) compounds for ocular diseases such as age-related macular degeneration.
• Collaboration for Potential ALS Treatments. Three prominent philanthropic organizations - The Angel Fund, The ALS Therapy Alliance and Project ALS - dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) financed a new collaboration between RXi and one of the world's leading ALS researchers, Robert Brown, M.D., D.Phil, Chair of the Department of Neurology at the University of Massachusetts Medical School in Worcester.
• Received 2009 RNAi Frost & Sullivan Award. RXi received Frost & Sullivan's 2009 North American RNAi Therapeutic Design & Delivery Technology Innovation of the Year Award for the development of its proprietary RNAi compounds, rxRNA™, and advanced delivery approaches, including the sdrxRNA™.
• Continued the Advancement of RNAi Therapeutics Platform. RXi's comprehensive therapeutic platform, which is comprised of next generation rxRNA compounds and advanced delivery approaches, continues to produce promising pre-clinical data. Specifically, data has been presented at numerous conferences demonstrating the robustness and potential for broad-based applications using sd-rxRNA compounds in diverse therapeutic areas that may enable multiple opportunities for developing a sustainable pipeline of RNAi therapeutics for unmet medical needs in both local and systemic applications.

2009 Financial Highlights:

For the year ended December 31, 2009, our net loss was approximately $18.4 million, an increase of approximately $4.0 million, or 28%, compared with a net loss of $14.4 million for the year ended December 31, 2008. The Company had 16,207,625 common shares outstanding at December 31, 2009, as compared with 13,763,231 common shares outstanding at December 31, 2008. The Company had a net loss per share on both a basic and diluted basis of $1.24 and $1.09 at December 31, 2009 and December 31, 2008, respectively.

For the fourth quarter of 2009, our net loss was approximately $6.1 million, or $0.38 per share on both a basic and diluted basis, compared with a net loss of $4.0 million, or $0.29 per share on both a basic and diluted basis, for the fourth quarter of 2008.

Research and development expenses for the fourth quarter of 2009 were $2.4 million, including approximately $0.6 million in non-cash share-based compensation, compared with $2.0 million, including $0.1 million in non-cash share-based compensation, for the fourth quarter of 2008. The increase of $0.4 million, or 18%, was primarily due to an increase in non-employee non-cash share-based compensation as well as compensation and related expenses from the additional headcount to support the Company's collaborations and internal discovery efforts.

For the year ended December 31, 2009, research and development expenses were approximately $8.9 million, including approximately $2.2 million in non-cash share-based compensation, an increase of approximately $1.8 million, or 26%, compared with research and development expenses of $7.1 million for the year ended December 31, 2008, which included approximately $1.9 million in non-cash share-based compensation. This increase was due to higher staff-related costs, supplies and increased patent application and prosecution expenses that were $1.6 million higher in 2009 than in 2008.

General and administrative expenses for the fourth quarter of 2009 were $1.9 million including $0.6 million in non-cash share based compensation, compared with $2.0 million including $0.6 million in non-cash share-based compensation for the fourth quarter of 2008. The decrease of $0.1 million, or 4%, was primarily due to the non cash share based compensation expense associated with stock warrants expensed in the fourth quarter of 2008.

For the year ended December 31, 2009, general and administrative expenses were $8.6 million, compared with $7.5 million for the year ended December 31, 2008. The increase of $1.1 million, or 15%, was primarily due to higher staff-related costs as well as higher costs related to professional service fees in association with business activities, including $2.0 million in non-cash share based compensation, and $1.1 million in costs related to warrants and common stock issued in exchange for services.

As of December 31, 2009, cash and cash equivalents totaled $5.7 million, compared with cash and cash equivalents of $9.9 million at December 31, 2008. This decrease was due to cash used in operations of $11.8 million for the twelve months ended December 31, 2009 partially offset by the proceeds from RXi's registered direct offering in July 2009 where RXi raised approximately $7.8 million in net proceeds after deducting placement agent fees and other offering costs.